Ten-Year Follow-Up of a Randomized Trial of Pravastatin in Heart Transplant Patients

普伐他汀 医学 随机对照试验 心脏移植 内科学 心脏病学 移植 胆固醇
作者
Jon A. Kobashigawa,J. Moriguchi,Hillel Laks,Liane Wener,A. Hage,Michèle A. Hamilton,Gregory Cogert,A. Márquez,Maria Espejo Vassilakis,Jignesh Patel,Lawrence A. Yeatman
出处
期刊:Journal of Heart and Lung Transplantation [Elsevier BV]
卷期号:24 (11): 1736-1740 被引量:171
标识
DOI:10.1016/j.healun.2005.02.009
摘要

Background

Outcomes from this trial's first year data demonstrated significant benefit in heart transplant patients treated with pravastatin in cholesterol levels, survival, rejection with hemodynamic compromise, the development of cardiac allograft vasculopathy, and decreased natural killer cell cytotoxicity. Other heart transplant studies have shown similar benefit. We now report the 10-year follow-up of this study.

Methods

Ninety-seven heart transplant recipients were randomized to pravastatin (n = 47) or no pravastatin (n = 50) within 2 weeks after surgery both in combination with cyclosporine and corticosteroids. Ten-year outcomes include survival, cholesterol levels, and development of cardiac allograft vasculopathy documented by coronary angiography.

Results

Forty-two percent of the control patients crossed over to pravastatin treatment during the second year of the study, and 81% of the control patients were eventually placed on statin therapy by the 10-year follow-up. The control group had subsequent low and comparable cholesterol levels in Years 2 to10 of the study compared with the patients originally randomized to pravastatin. Intent-to-treat analysis demonstrated that the pravastatin group compared with control had increased 10-year survival (68% vs 48%, p = 0.026). The 10-year freedom from angiographic cardiac allograft vasculopathy and/or death in the pravastatin group was significantly greater compared with the control group (43% vs 20%, p = 0.009).

Conclusion

The 10-year follow-up of this study suggests that the use of pravastatin in heart transplant patients maintains survival benefit and appears to reduce the development of cardiac allograft vasculopathy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
bkagyin应助和花花采纳,获得10
2秒前
2秒前
深情的雁露完成签到,获得积分10
3秒前
yixiaolou完成签到,获得积分10
4秒前
宇宇发布了新的文献求助10
5秒前
loong发布了新的文献求助10
5秒前
Blue发布了新的文献求助10
6秒前
失眠的夜梦完成签到,获得积分10
8秒前
谓风完成签到,获得积分10
9秒前
恋雅颖月应助乐观的寻绿采纳,获得10
9秒前
Shrine完成签到,获得积分10
9秒前
英姑应助紫色奶萨采纳,获得10
11秒前
12秒前
13秒前
希望天下0贩的0应助Jay采纳,获得10
14秒前
14秒前
爆米花应助zewangguo采纳,获得10
15秒前
斯文败类应助loong采纳,获得10
16秒前
深情安青应助Xin采纳,获得10
17秒前
和花花发布了新的文献求助10
17秒前
摩卡完成签到,获得积分10
18秒前
19秒前
20秒前
端庄毛巾完成签到,获得积分10
20秒前
21秒前
21秒前
21秒前
张雯思发布了新的文献求助10
23秒前
ding应助Nugget采纳,获得10
23秒前
幸福大白发布了新的文献求助30
26秒前
wdy111举报ZZZ求助涉嫌违规
27秒前
zewangguo发布了新的文献求助10
27秒前
28秒前
高大的冰双完成签到,获得积分10
29秒前
31秒前
987完成签到 ,获得积分10
32秒前
loong完成签到,获得积分10
32秒前
紫色奶萨发布了新的文献求助10
33秒前
zewangguo完成签到,获得积分10
33秒前
34秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989406
求助须知:如何正确求助?哪些是违规求助? 3531522
关于积分的说明 11254187
捐赠科研通 3270174
什么是DOI,文献DOI怎么找? 1804901
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809174